Article
Prognostic effects of TERT promoter mutations are enhanced by coexistence with BRAF or RAS mutations and strengthen the risk prediction by the ATA or TNM staging system in differentiated thyroid cancer patients.
Cancer - 1 May 2016
Song Young Shin, Lim Jung Ah, Choi Hoonsung, Won Jae-Kyung, Moon Jae Hoon, Cho Sun Wook, Lee Kyu Eun, Park Young Joo, Yi Ka Hee, Park Do Joon, Seo Jeong-Sun
Abstract excerpt
BACKGROUND: Recent reports suggest that mutations in the promoter of the gene encoding telomerase reverse transcriptase (TERT) affect thyroid cancer outcomes. METHODS: In all, 551 patients with differentiated thyroid cancer (DTC) enrolled in this study. The median follow-up duration was 4.8 years (interquartile range, 3.4-10.6 years). RESULTS: TERT promoter mutations were detected in 25 DTCs (4.5%): 2.8% in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.